Cervical cancer is a leading cause of cancer-related death in women, and it is known to have a poor prognosis. This is because, patients develop progressive or recurrent tumours after primary treatment, and the major reason for tumour recurrence is the presence of cancer stem cells (CSCs). It is known that retinoic acid (RA) has potential therapeutic effects on cervical cancer. However, the possible mode of action of RA in cervical cancer cells, and its relation to CSCs remains elusive. The aim of this research was to determine the anticancer effect of RA in cervical cancer cells (HeLa). HeLa cells were treated by various concentrations of RA ranging from 5-50µM to determine the effect of RA on cell viability, and cell proliferation. Both experiments were carried out using Celltiter-glo 2.0 assay and CyQuant NF assay, respectively. Apoptosis activity was determined using Caspase-Glo 3/7 assay. Immunofluorescent staining was conducted to detect the expression of differentiation marker (pan-keratin), and stem cell markers (CD133 and SSEA4) on untreated and treated HeLa cells with 10µM of RA. The findings showed that RA reduced cell viability and proliferation in a dose-dependent manner by 12-83% and 22-86%, respectively. However, a change in caspase3/7 activity between untreated, and 10µM RA-treated Hela cells were not detected indicating absence of apoptotic activity. The study also revealed that expression of differentiation marker (pan-keratin) was up-regulated, while expressions of stem cell markers (CD133 and SSEA4) were down-regulated. In addition, morphology of HeLa cells displayed a more differentiated phenotype that is less proliferative upon RA treatment. These findings suggest that RA showed its anticancer effect on cervical cancer cells by exhibiting cytotoxicity, inhibiting proliferation capacity, and inducing differentiation of cervical cancer cells. This finding shows that retinoic acid may potentially serve as a potent targeted therapy for cervical cancer and other cancers possessing CSCs within its tumors.
INTRODUCTION
Cervical cancer is the third common female disease worldwide after breast and colorectal cancer, with about half a million cases a year with 80% cases in less-developed countries, and about 25% in developing countries [1, 2] . The main cause of cervical cancer is the Human papillomavirus (HPV) infection [1] . HPV is a virus that is transmitted sexually [3] . Although, most HPV infection is harmless and clears spontaneously, persistent infection with highrisk human papillomavirus subtype, especially type 16 and type 18 greatly increases the risk of cervix cancer [4, 5] . HPV virus infects epithelial cells, and induce hyperproliferative lesions [6] .
The current treatment strategies for cervical cancer are electro-surgery and cryosurgery (remove and cure premalignant lesions), while chemotherapy and radiotherapies are usually used for high-risk premalignant lesions, and carcinomas [7] . However, the major problem with current treatments is that patients with cervical cancer showed tumour recurrence where the tumour characteristics become more malignant after treatment [7] . The main reason for tumour recurrence is pressumed to be due to the population of cancer stem cell (CSC) within the tumour. In the cervix, the de-differentiation of mature cells, and mutation of stem cells in normal cervical tissue is believed to be the source of cervical cancer stem cells [8] . Based on previous studies, CSCs have been identified in several cervical cancers cell line such as SiHa, CaLo, C-33A [9] . CSCs have properties similar to normal stem cells such as self-renewal, slow cycling capacity, multilineage differentiation potential, asymmetric division, and tumorigenicity [10, 11] .
All traditional chemotherapies target proliferating cells, potentially missing the slower dividing CSCs within a tumour, allow the CSCs to survive, and be resistant to treatment. These abilities of the CSCs are responsible for tumour metastasis, relapse, and chemo/radio-resistance as a result of reactivation of proliferation by the surviving CSCs post treatment [12] . Therefore, it is necessary to identify effective drugs to target CSC enriched cervical cancer, which are still difficult to treat, and lack effective treatment for cervical cancer [10] .
As it is known that stem cells differentiate into more matured/specialised cells with limited proliferative capacity, current anti-cancer drug treatments are focused more on establishing differentiation based therapies [13] . The principle of differentiation therapies is to convert CSC population within a tumour into a more differentiated phenotype, and to make them respond to a second drug, or therapy that targets differentiated cancer cells [13] .
Retinoic acid is a metabolite of vitamin A. Retinoic acid was previously discovered to have potential in preventing cancer development. The function of this compound in biological processes are maintenance of epithelial cell, differentiation, proliferation, and apoptosis [14] . It also acts as inhibitors of chemical and viral carcinogenesis [14] . Previous studies on retinoic acid showed that it suppressed the growth, and development of various types of tumors such as skin, bladder, lung, prostate, and breast cancers [15] . Besides that, addition of retinoic acid to human tumour xenograft in mice resulted in growth arrest, and differentiation of tumour cells [16, 17] . Previous studies also reported that retinoic acid, a promising chemotherapy agent in acute promyelocytic leukemia (APL), destroys the fusion oncogene such as autophagy [17] . In acute promyelocytic leukemia patients, retinoic acid-induced apoptosis mediated by paracrine action of tumour-selective death ligand TRAIL [18] . Moreover, retinoic acid in combination with histone deacetylase inhibitors SL14 has an antitumour effect, and is a therapeutic candidate to treat lung cancer [19] .
Thus, an understanding of anti-cancer effect of retinoic acid in cervical cancer cells, is important for developing the usage of retinoids in therapeutic trials. However, the action/mechamnism of retinoic acid in cervical cancer still remains unclear. Therefore, this project looks into the anti-cancer effect of retinoic acid, and its possible mechanism of action based on the ability to induce apoptosis in cervical cancer cells
METHODOLOGY

Cell Culture
Cervical cancer cell line (Hela cells) were cultured in T25 flasks and maintained at 37° and 5% of CO2 in DMEM/F12+Glutamax TM 1 (Life Technologies, USA), supplemented with fetal calf serum (FCS), and antibiotic-antimycotic (100 U/mL penincilin, 100µg of streptomycin/0.25µg/ml) (Invitrogen). Cervical cancer cell line (Hela cells) was passaged, three times a week at 60-70% cell confluency.
Determination of Cell Viability and Proliferation
60-70% confluency of cell cultures were used to test cell viability (cytotoxicity) and proliferation. 4×103 cells per 100-μl were seeded in a 96-well plate. After 24 hours of incubation, retinoic acid was added at different concentrations (5, 10, 15, 20, 30 and 50μM) and incubated for 24 hours. Examination of cell viability was done via Celltiter-Glo® 2.0 Assay kit. 100μl of celltiter-glo® 2.0 reagent was added per well and contents were mixed for 2 minutes on a vortex mixer. To stabilize luminescent signal, plate was incubated for 10 minutes before the reading was taken. Meanwhile, the cell proliferation was examined via Cyquant® NF assay kit. Old media was removed post 24 hours of RA treatment. Cells were then resuspended in 50μL 1×Hank's Balanced Salt Solution (HBSS). 50μl 2× dye binding solution (CyQuant) was dispensed into each well containing cell culture. The microplate well were covered and incubated at 37°c for 2 hours before reading was taken. The activity for both the assays was read at 490nm by installing a blue filter using a GloMax®-Multi Microplate Multimode Reader (Promega GloMax®-Multi Detection System). Experiments were done in three independent experiments and the results were averaged.
Caspase-Glo® 3/7 Apoptosis Assay System
Cell cultures of 60-70% confluency were used for the apoptosis assay. 4×10 3 cells per 100-µl were seeded in a 96-well plate. The cells were incubated for 24 hours. After that, 10µM of retinoic acid and 20nM of taxol was added, respectively, and the cells were again incubated for 24 hours. 10µM of retinoic acid was selected as it showed 50% reduction in cell proliferation assay. After 24 hours of incubation, 96well plate containing cultured cells were equilibrated to room temperature. Caspase-Glo® 3/7 reagent was added to each well that contained control, 10µM of retinoic acid, and 20nM of taxol. The plate wells were covered and mixed gently, and incubated for 2 hours at room temperature. Fluorescence intensity of samples was measured at 490nm by installing a blue filter using a GloMax®-Multi Microplate Multimode Reader (Promega GloMax®-Multi Detection System). Caspase activity luminescence (RLU) percentage of apoptosis for control (untreated cell) was set to 1% which indicated natural apoptosis activity whereas the retinoic acid and taxol (positive control; apoptosis inducing drug) treated Hela cells apoptotic activity levels were normalised to the control.Experiments were done in three independent experiments and the results were averaged.
Immunofluorescence Microscopy
Staining of Intracellular Marker (Pan-Keratin) and Surface Marker (CD133 and SSEA4)
Hela cells were stained with Intracellular marker (pankeratin) to detect the presence of differentiation and surface markers (CD133 and SSEA4) to detect the stemness via presence of CSCs in untreated, and RA treated HeLa cells. In 24-well plates, 4×10 4 cells per 500ml were grown separately on coverslips for 24 hours. 10-µM of retinoic acid was added, and the cells were incubated for 24 hours. The cells were then fixed with 1% of paraformaldehyde (PFA) in FCS 1% for 20 minutes. The over slips were washed once with PBS (phosphate-buffered saline) per well, and transferred to new 24 well plates. For intracellular marker, the cells were permeabilized by adding 0.1% of Triton X-100 (Calbiochem) in PBS for 20 minutes, and washed once with PBS prior to the addition of primary antibody. The primary antibodies anticytokeratin antibody (CK3-6H5 FITC, human), (CD133/1-VioBright (TM) FITC) and (anti-SSEA4-FITC, human) were added into each well, and incubated overnight in a dark area. The cells were washed with PBS. Secondary antibodies, mouse-IgG1-viobright FITC, and REA control(s) FITC along with 1:1000 (DAPI) for nuclear staining were added to the cells and incubated for another 2 hours. The cells were then washed with PBS, and the cover-slips were transferred on to slides with mounting medium (Dako), and sealed with nail polish. Appropriate negative control (secondary antibody only) was used for this study. The cells were imaged by using an inverted immunofluorescence microscopy.
Statistical Analysis
Statistical and graphical analysis was done in Microsoft Excel and GraphPad Prism-7. Paired t-test with two-tailed distribution was used to compare retinoic acid-treated and untreated cervical cancer cells. The results are presented in a mean±SEM for (cytotoxicity, cell proliferation and apoptosis (caspase activity)). The significance is shown as follows: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
RESULTS AND DISCUSSION
Retinoic Acid Reduces Cell Viability and Proliferation of Cervical Cancer Cells
Cell viability of HeLa cells was determined using CellTiter-Glo® 2.0 Assay. Based on Figures 1, 2 and 3 , retinoic acid showed a dose-dependent effect in HeLa cells. As shown in Figure 1 , retinoic acid at doses 5, 10, and 15 µM showed a small decline in cell viability, which indicates a minimal level of cytotoxic effect in HeLa cells, ranging from 12-21%. However, the most significant reduction in cell viability was observed at 50µM, (83%, p<0.01), followed by 30µM, (59%, p<0.01), and 20µM, (36%, p<0.01). This result showed that retinoic acid significantly exhibited cytotoxicity effect towards HeLa cells at higher doses (20, 30 and 50µM). To elucidate whether retinoic acid inhibited cell proliferation, the proliferation activity of HeLa cells was determined. As shown in Figure 3 , cell proliferation capacity showed a dramatic decrease in comparison to the cell viability at all doses of retinoic acid (5, 10, 15, 20, 30 and 50µM); 22% (p<0.001), 46% (p<0.05), 59% (p<0.05), 62% (p<0.01), 73% (p<0.001) and 86% (p<0.0001), respectively. The marked reduction in cell proliferation despite being viable may suggest that the surviving HeLa cells may have undergone differentiation. Based on a previous study it demonstrated that inhibition of cell growth can be the early indications of induced differentiation in cultured neuroblastoma cells [20] .
In addition, the morphological changes in HeLa cells upon retinoic acid treatment showed a more differentiated phenotype that is less proliferative (see Figure 4 ). The cell density began to decrease and the cells that were exposed to higher doses of retinoic acid lost their normal morphology and shape; HeLa cells appeared slightly rounded in shape, and contracted with the increasing concentration of retinoic acid. At 30 and 50µM of retinoic acid, most of the cells appeared almost round in shape, which can be presumed that the surviving cancer cells could be cancer stem cells (CSCs) that are drug resistant (see Figure 4 ). The CSCs are known to live longer, are resistant to the effects of drugs, and have a quiescent slow-cycling phenotype [12, 21, 22] . 
Retinoic Acid Did Not Induce Apoptosis in Cervical Cancer Cells
Apoptosis is a physiological function of programmed cell death, and is characterised by distinct morphological characteristics such as cell shrinkage, chromatin condensation, dense cytoplasm, blebbing of plasma membrane, loss of nuclear membrane integrity, and eventually apoptotic bodies forms [23] . 10µM of retinoic acid was selected for apoptosis assay as it showed 50% reduction in cell proliferation assay (Figure 2) . Treatment with 10µM of retinoic acid (0.98%) showed negligible changes in apoptosis induction, while 20nM of taxol (1.71%) showed clear and significant increase in caspase3/7 activity which indicates apoptosis.
In general, as shown in Figure 5 , a small dose of taxol was sufficient to induce apoptosis in HeLa cells, while retinoic acid did not induce apoptosis even at a higher dose. Thus, this data suggests that retinoic acid did not induce caspase -3 /7 activity in HeLa cells [24] . The finding from this assay suggest that growth suppression induced by retinoic acid does not cause the death of cancer (tumour) cells, but the cells get arrested during the G1 stage of the cell cycle [25] . 
Retinoic Acid Induces Differentiation of Cervical Cancer Cells
Pan-keratin is an epithelial differentiation marker, and specifically targets luminal epithelial cells. CD133 is a cervical cancer stem cell marker, and highly expressed in HeLa cells that display stem-like characteristics such as differentiation, anti-apoptotic, proliferation, chemo/radio-resistance, self-renewal, and tumorigenicity [9] . SSEA4 is a human embryonic stem cell marker which displays characteristics as indefinite self-renewal and pluripotency [26] .
Based on Figure 6 , upon retinoic acid treatment, the expression of differentiation marker showed an increase in pan-keratin. In contrast, expression of CD133 and SSEA4 decreased. The immunofluorescent staining suggests that, retinoic acid may exert its mechanism by inducing differentiation, and shifts the cervical cancer cells to a more differentiated and less proliferative cell type by up-regulating the differentiation marker (pankeratin), and down-regulating the stem cells markers (CD133 and SSEA4). Previous studies also showed that stem cell markers such as SSEA4 are highly expressed in CSC enriched tumours while differentiation marker, pan-keratin is highly expressed in more differentiated cells [27] . Other studies showed that SP cells express high expression of CD133 marker that were isolated from the HeLa cell line, which shows stem like properties such as self-renewal, proliferation, and differentiation. These SP cells were found to be resistant to chemotherapy [28] . In contrast, SSEA4 expression in general is known to be diminished/down regulated during the differentiation process [29] .
Thus, based on the findings of this study, it can be concluded that retinoic acid induced differentiation by shifting cervical cancer cells towards a more differentiated, and less proliferative cell type instead of inducing cell death via apoptosis. As more differentiated cancer cells are often easier to be treated, a second anticancer agent can be used to target, and kill the differentiated CSCs post RA treatment. These findings also show that retinoic acid can be a potent targeted anticancer drug in the treatment of cervical as well as other cancers that are enriched with cancer stemcells (CSCs).
Figure 6
Retinoic acid influences expression of differentiation marker (pan-keratin) and stem cell markers (CD133 and SSEA4) in cervical cancer cell (HeLa). Stem cell markers were down-regulated after treatment with 10μM of retinoic acids and differentiation marker was increased after the treatment
CONCLUSION
Cervical cancer is a common type of gynaecological malignancy, and can result in death if left untreated. Intra-tumour genetic heterogeneity in cervical cancer leads to metastasis, poor chemo/radio-therapy response, and recurrence of the disease. The major factor that contributes to the recurrence of the cancer in cervical cancer is the presence of cancer stem cell (CSCs). This study showed that retinoic acid exerts anticancer properties by effectively reducing cell proliferation and cell viability of HeLa cells. In addition, a downregulation of cancer stem cell marker and an upregulation of differentiation marker expression as well as morphological changes in HeLa cells in the presence of retinoic acid, correlate well with the significant anticancer properties of retinoic acid. Therefore, the findings of this study show that retinoic acid may potentially serve as a potent targeted therapy for cervical cancer. Thus, retinoic acid in combination with other anticancer drugs might act efficiently, or additively to suppress the growth of tumour/cancer, and provide an effective targeted therapy for cervical cancer. These findings also provide a new avenue for adjuvant treatment in treating cancers that are enriched with CSCs. However, further studies on retinoic acid are required to find the exact mechanism of action for better 
